Table 2.

Incidence of Plasmacytomas in Indomethacin Treated Mice

Exp.Pristane DoseINDO Dose μg/mL (days given)No. MicePercent of Mice With PCTs on Day:
150175200225250275300
0.5 × 3 40F 15 15 30 55  —   —   —  
1A 0.5 × 3 20 (D0-219) 37F  —   —   —  
0.5 × 3 25M, F 12 16 36 36 56 76 76 
2A 0.5 × 3 20 (D0-D70) 24M, F 12.5 29.2 41.7 41.7 70.8 70.8 
2B 0.5 × 3 20 (D0-295) 12M 
2C 0.5 × 3 20 (D.50-295) 24M, F 8.3 12.5 16.6 25 25 
2D 0.5 × 3 20 (D70-295) 23M, F 17.3 21.8 21.8 21.8 30.2 30.2 
0.2 × 3 35M, F 8.5 17.2 17.2 34.2 34.2 40 43 
3A 0.2 × 3 20, 10 (D0-310) 36M, F 5.5 5.5 5.5 5.5 
3B 0.2 × 3 10 (D0-310) 36M, F 2.7 2.7 5.5 5.5 5.5 5.5 
3C 0.2 × 3 20, 10 (D60-310) 36M, F 2.7 5.5 5.5 11.5 17.4 24 27.6 
DISC 23M, F 4.3 4.3 4.3 4.3 4.3 30.3* 
4A DISC 20 D0-361 23F  0** 
Exp.Pristane DoseINDO Dose μg/mL (days given)No. MicePercent of Mice With PCTs on Day:
150175200225250275300
0.5 × 3 40F 15 15 30 55  —   —   —  
1A 0.5 × 3 20 (D0-219) 37F  —   —   —  
0.5 × 3 25M, F 12 16 36 36 56 76 76 
2A 0.5 × 3 20 (D0-D70) 24M, F 12.5 29.2 41.7 41.7 70.8 70.8 
2B 0.5 × 3 20 (D0-295) 12M 
2C 0.5 × 3 20 (D.50-295) 24M, F 8.3 12.5 16.6 25 25 
2D 0.5 × 3 20 (D70-295) 23M, F 17.3 21.8 21.8 21.8 30.2 30.2 
0.2 × 3 35M, F 8.5 17.2 17.2 34.2 34.2 40 43 
3A 0.2 × 3 20, 10 (D0-310) 36M, F 5.5 5.5 5.5 5.5 
3B 0.2 × 3 10 (D0-310) 36M, F 2.7 2.7 5.5 5.5 5.5 5.5 
3C 0.2 × 3 20, 10 (D60-310) 36M, F 2.7 5.5 5.5 11.5 17.4 24 27.6 
DISC 23M, F 4.3 4.3 4.3 4.3 4.3 30.3* 
4A DISC 20 D0-361 23F  0** 

Summary of statistical analysis. At each time point the proportions of animals with PCTs were compared using Fisher's exact test (reported results are for two-sided test). There was no significant difference ( P > .4) between the tumor rates in groups 2 and 2A. At the 5% significance level ( P < .05), the tumor rates for groups 2B and 2C were significantly lower than that for group 2 from day 200 on, and the tumor rate for group 2C was significantly lower than that for group 2 from day 225 on. At the 0.5% significance level ( P < .005), the tumor rates for groups 2B and 2C were significantly lower than that for group C from day 225 on, and the tumor rate for group 2D was significantly lower than that for group 2 from day 275 on. There were no significant differences in tumor rates among groups 2B, 2C and 2D (although this is due in large part to the small sample size in group 2B). There was no sustained significant difference between groups 3 and 3C (the tumor rate in group 3C was significantly lower, with P = .038, at 225 days only). At the 5% significance level, the tumor rate for group 3A was significantly lower than that for group 3 from 175 days on, and the rate for group 3B was significantly lower than that for group 3 from 225 days on. At the 0.5% significance level, the tumor rates for both groups 3A and 3B were significantly lower than that for group 3 from 225 days on. There were no significant differences between groups 3A and 3B. The tumor rates for groups 3A and 3B were significantly lower than that for group 3C ( P < .05) from day 275 on.

Abbreviations: M, male; F, female.

*

At day 361, 38.9% of the mice had PCTs.

Mice autopsied at days 361, 397.

Close Modal

or Create an Account

Close Modal
Close Modal